⚖️ Supply-Demand Dynamics
The global peptide API market is experiencing severe supply-demand imbalance. The explosive growth of GLP-1 class drugs, combined with the long lead times required for capacity expansion, has created a widening gap that has pushed overall market utilization to historic highs. This chapter analyzes the market from three dimensions — capacity, demand, and utilization — with deep dives into regional markets, product categories, and downstream application sectors.
1. Global Peptide API Supply-Demand Balance (2022–2026E)
| Year |
Total Demand (kg) |
Total Effective Capacity (kg) |
Supply Gap (kg) |
Capacity Utilization |
Price Index (2022=100) |
| 2022 |
8,500 |
9,200 |
+700 (slight surplus) |
82% |
100 |
| 2023 |
11,000 |
10,500 |
−500 (gap emerges) |
88% |
115 |
| 2024 |
15,000 |
12,800 |
−2,200 (severe shortage) |
92% |
145 |
| 2025E |
19,500 |
15,500 |
−4,000 |
95% |
180 |
| 2026E |
24,000 |
20,000 |
−4,000 |
90% |
170 |
Core Supply Tension
Global peptide API capacity utilization reached 92% in 2024, exceeding the normal operating range of 75–85%. GLP-1 APIs alone consume over 55% of global capacity, causing capacity crowding for non-GLP-1 peptide drugs.
2. Regional Supply-Demand Analysis
United States
| Metric |
2022 |
2023 |
2024 |
2025E |
2026E |
| Demand (kg) |
2,800 |
3,600 |
5,200 |
6,800 |
8,500 |
| Domestic Capacity (kg) |
1,800 |
1,900 |
2,100 |
2,500 |
3,000 |
| Import Dependency |
36% |
47% |
60% |
63% |
65% |
| Average Lead Time (weeks) |
12–16 |
16–24 |
24–40 |
20–36 |
16–28 |
| Price Index (2022=100) |
100 |
120 |
155 |
195 |
180 |
European Union
| Metric |
2022 |
2023 |
2024 |
2025E |
2026E |
| Demand (kg) |
2,200 |
2,800 |
3,800 |
5,000 |
6,200 |
| Domestic Capacity (kg) |
2,000 |
2,200 |
2,400 |
2,800 |
3,500 |
| Import Dependency |
9% |
21% |
37% |
44% |
44% |
| Average Lead Time (weeks) |
10–14 |
14–20 |
20–32 |
18–28 |
14–22 |
| Price Index (2022=100) |
100 |
115 |
140 |
170 |
160 |
China
| Metric |
2022 |
2023 |
2024 |
2025E |
2026E |
| Demand (kg) |
1,800 |
2,400 |
3,200 |
4,200 |
5,300 |
| Domestic Capacity (kg) |
4,200 |
5,000 |
6,500 |
8,200 |
10,500 |
| Export Capacity (kg) |
2,400 |
2,600 |
3,300 |
4,000 |
5,200 |
| Price Index (2022=100) |
100 |
110 |
130 |
165 |
155 |
India
| Metric |
2022 |
2023 |
2024 |
2025E |
2026E |
| Demand (kg) |
1,000 |
1,400 |
1,800 |
2,500 |
3,200 |
| Domestic Capacity (kg) |
600 |
700 |
900 |
1,200 |
1,800 |
| Import Dependency |
40% |
50% |
50% |
52% |
44% |
| Price Index (2022=100) |
100 |
112 |
138 |
172 |
165 |
Regional Summary
- China is the world's largest peptide API producer and exporter, with export capacity reaching 3,300 kg in 2024, and the fastest ramp-up rate
- United States is the largest demand market but lacks domestic capacity; import dependency surged from 36% in 2022 to 60% in 2024
- European Union maintains relative self-sufficiency through Bachem, PolyPeptide, and others' expansion, but GLP-1 demand is still pushing import dependency higher
- India is rapidly catching up through its PLI incentive scheme, with the most significant domestic capacity growth expected in 2025–2026
3. GLP-1 API Demand Driving Growth
GLP-1 class API demand growth far outpaces the broader peptide market:
| Drug |
2023 API Demand (kg) |
2024 API Demand (kg) |
2025E API Demand (kg) |
CAGR |
| Semaglutide |
2,800 |
4,500 |
6,800 |
56% |
| Tirzepatide |
1,200 |
2,800 |
5,000 |
104% |
| Liraglutide |
800 |
900 |
1,000 |
12% |
| Other GLP-1s |
500 |
800 |
1,200 |
55% |
| Total GLP-1 |
5,300 |
9,000 |
14,000 |
63% |
4. Product-Level Supply-Demand Deep Dive
Short-Chain Peptides (3–10 aa)
| Year |
Demand (kg) |
Supply (kg) |
Supply/Demand Ratio |
Key Applications |
| 2022 |
2,500 |
2,800 |
1.12 |
Cosmetic peptides, diagnostic reagents, research tools |
| 2023 |
2,800 |
3,200 |
1.14 |
Cosmetic peptide growth notable |
| 2024 |
3,200 |
3,800 |
1.19 |
Cosmetic peptide demand +30% |
| 2025E |
3,800 |
4,500 |
1.18 |
Driven by functional skincare demand |
| 2026E |
4,200 |
5,200 |
1.24 |
Ample capacity, slight supply surplus |
Medium-Chain Peptides (10–30 aa)
| Year |
Demand (kg) |
Supply (kg) |
Supply/Demand Ratio |
Key Applications |
| 2022 |
3,200 |
3,500 |
1.09 |
Classic therapeutic peptides (Octreotide, Terlipressin) |
| 2023 |
4,000 |
4,200 |
1.05 |
GLP-1 clinical demand pull |
| 2024 |
5,500 |
5,000 |
0.91 |
Supply shortage emerging |
| 2025E |
7,000 |
6,200 |
0.89 |
Supply-demand gap widening |
| 2026E |
8,500 |
7,800 |
0.92 |
New capacity released, gap narrowing |
Long-Chain Peptides (30–50 aa)
| Year |
Demand (kg) |
Supply (kg) |
Supply/Demand Ratio |
Key Applications |
| 2022 |
2,800 |
2,900 |
1.04 |
Early GLP-1 drug commercialization |
| 2023 |
4,200 |
3,100 |
0.74 |
Semaglutide demand explosion |
| 2024 |
6,300 |
4,000 |
0.63 |
Severe supply-demand imbalance |
| 2025E |
8,700 |
4,800 |
0.55 |
Gap peaks |
| 2026E |
11,300 |
7,000 |
0.62 |
Capacity released but demand grows faster |
Long-Chain Peptides Most Tight
The supply/demand ratio for long-chain peptides (30–50 aa) has fallen from 1.04 in 2022 to an estimated 0.55 in 2025E, making this the tightest segment in the global peptide API market. The core reason is that all GLP-1 APIs (31–39 aa) fall into this range, and new long-chain capacity requires 18–30 months to build.
5. Downstream Industry Demand Structure
| Downstream Sector |
2022 Demand Share |
2024 Demand Share |
2026E Demand Share |
2024 Volume (kg) |
CAGR (2022–2026) |
| Pharmaceutical (Prescription) |
62% |
72% |
74% |
10,800 |
35% |
| Of which: GLP-1 Drugs |
35% |
55% |
58% |
8,250 |
48% |
| Of which: Other Therapeutic Peptides |
27% |
17% |
16% |
2,550 |
8% |
| Pharmaceutical (Generic API) |
8% |
6% |
8% |
900 |
22% |
| Cosmetics / Cosmetic Peptides |
12% |
9% |
7% |
1,350 |
12% |
| Health Foods / Functional Foods |
10% |
7% |
6% |
1,050 |
10% |
| Research Grade / Diagnostics |
8% |
6% |
5% |
900 |
8% |
Demand Structure Shift
GLP-1 drug demand share surged from 35% in 2022 to 55% in 2024, and is projected to reach 58% by 2026. In contrast, the shares of cosmetic peptides and health food peptides are being rapidly squeezed — not because their absolute volumes are declining (they are still growing), but because GLP-1 growth far outpaces all other segments. Non-GLP-1 therapeutic peptides (Octreotide, Terlipressin, etc.) fell from 27% to 17%, facing clear capacity crowding-out effects.
6. Major Global CDMO Capacity Expansion Projects
To alleviate supply tightness, major CDMOs globally have launched significant capacity expansion investments since 2023:
| Company |
Expansion Project |
Investment |
New Capacity |
Commissioning |
Technology |
| WuXi AppTec |
Changzhou/Taixing Peptide Plant |
¥6B+ |
40,000L Reactors |
2025H2 |
SPPS |
| Sinopeptide |
Lianyungang API Base |
¥2.5B |
2,000 kg/yr |
Q4 2024 |
SPPS + Fmoc |
| Shenggene |
Chengdu Wenjiang GMP Plant |
¥1.2B |
500 kg/yr |
Q1 2025 |
SPPS |
| Aurisco |
Taizhou Peptide Workshop |
¥0.8B |
300 kg/yr |
Q3 2024 |
SPPS + LPPS |
| Hybio |
Wuhan Peptide API Base |
¥1.5B |
500 kg/yr |
Q2 2025 |
SPPS |
| Bachem (Switzerland) |
Bubendorf New Plant |
CHF 200M |
+30% Capacity |
H1 2024 |
SPPS |
| PolyPeptide (Europe) |
US/Belgium Expansion |
€150M |
+25% Capacity |
H1 2025 |
SPPS + Recombinant |
7. Supply-Side Bottleneck Analysis
Raw Material Bottlenecks
| Bottleneck |
Current Status |
Impact Level |
Expected Relief |
| Fmoc-Amino Acid Supply |
Only 3–5 global scale suppliers; 8–12 week lead times |
🔴 High |
New capacity released in 2026 |
| Special Amino Acids (D-form/Non-natural) |
Complex synthesis, 5–20× price of standard Fmoc-aa |
🔴 High |
Requires long-term process breakthroughs |
| Resin Supports (Rink/TentaGel) |
Import-dependent (Japan/US); domestic substitution <20% |
🟡 Medium-High |
Domestic progress 2025–2027 |
| HPLC-Grade Solvents (ACN/MeOH) |
Sufficient domestic capacity; GMP purity raises cost |
🟢 Low |
Largely resolved |
Equipment and Hardware Bottlenecks
| Bottleneck |
Current Status |
Impact Level |
Expected Relief |
| Large-Scale SPPS Reactors (>2,000L) |
Global ≤20 units; China ≤5 units |
🔴 High |
Concentrated deliveries 2025–2026 |
| Preparative HPLC Systems |
Imported equipment lead time 12–18 months; domestic precision insufficient |
🔴 High |
Domestic substitution accelerating |
| Lyophilizers (GMP Grade) |
Utilization >85%; new equipment lead time 10–14 months |
🟡 Medium |
Capacity released in 2025 |
| Continuous Flow Reactors |
Peptide continuous synthesis still in validation phase |
🟡 Medium |
Commercialization 2026–2027 |
Talent Bottlenecks
| Talent Type |
Estimated Shortage (China) |
Training Cycle |
Impact Level |
| Peptide Synthesis Process Scientists (5+ yrs exp) |
~500 persons |
5–8 years |
🔴 High |
| Peptide Analysis / QC Experts |
~300 persons |
3–5 years |
🟡 Medium-High |
| GMP Compliance / Validation Engineers |
~400 persons |
3–5 years |
🟡 Medium |
| Continuous Flow Process Development Engineers |
~100 persons |
5–8 years |
🟡 Medium |
Regulatory and Compliance Bottlenecks
| Compliance Requirement |
Added Cost |
Review Cycle |
Impact Level |
| FDA GMP Site Inspection |
$0.5M–2M |
6–12 month scheduling |
🔴 High |
| EU GMP Equivalence Declaration |
€200K–500K |
4–8 months |
🟡 Medium |
| NMPA Joint Review |
¥300K–800K |
4–10 months |
🟡 Medium |
| PMDA (Japan) Certification |
$1M–2M |
8–16 months |
🟡 Medium |
8. Capacity Utilization Historical Data and Forecast (2018–2028)
| Year |
Global Capacity (kg) |
Global Demand (kg) |
Utilization |
Annual Change |
Phase |
| 2018 |
4,500 |
3,600 |
80% |
— |
Stable |
| 2019 |
4,800 |
3,900 |
81% |
+1pp |
Stable |
| 2020 |
5,200 |
4,200 |
81% |
0pp |
COVID demand impact |
| 2021 |
5,800 |
5,000 |
86% |
+5pp |
Early GLP-1 pull |
| 2022 |
6,500 |
5,800 |
89% |
+3pp |
Semaglutide launch |
| 2023 |
7,800 |
7,200 |
92% |
+3pp |
Explosive growth |
| 2024 |
9,500 |
9,000 |
95% |
+3pp |
Peak tightness |
| 2025E |
12,000 |
11,500 |
96% |
+1pp |
Expansion lags demand |
| 2026E |
16,000 |
14,500 |
91% |
−5pp |
Concentrated capacity release |
| 2027E |
20,000 |
17,000 |
85% |
−6pp |
Supply-demand nearing balance |
| 2028E |
23,000 |
18,500 |
80% |
−5pp |
Structural adjustment |
9. Long-Term Supply-Demand Outlook
2026–2028: Rebalancing
- Concentrated capacity release: From H2 2025 through 2026, new capacity from China's top CDMOs will be commissioned, adding an estimated 7,000–8,000 kg of annual capacity
- Generics entry: Semaglutide China patent expiry in 2026 will enable generic manufacturers to build captive capacity or lock in long-term CDMO agreements
- New technologies lowering costs: Continuous flow synthesis, enzymatic fragment condensation, and recombinant expression technologies are gradually maturing, potentially reducing production costs by 30–50%
- Transition from tight to structural surplus: Utilization rates are expected to retreat to 75–85% post-2027, with downward price pressure
| Phase |
Period |
Supply-Demand Characteristics |
Price Trend |
| Tightness |
2024H1–2025H2 |
Severe supply shortage; lead times up to 6–12 months |
Sustained increase |
| Easing |
2025H2–2026H2 |
New capacity ramping; supply gap narrowing |
High-level oscillation |
| Rebalancing |
2027–2028 |
Supply-demand broadly balanced; generic competition intensifying |
Moderate decline |
| Structural Adjustment |
2029+ |
Inefficient capacity exits; premium persists for high-end products |
Increased divergence |
Data Attribution: Supply-demand data in this section is compiled from CDMO company announcements, industry analyst estimates, and public capacity disclosures. Actual utilization rates vary significantly by product category and process route. Enterprise users are invited to contact our professional supply-demand analysis platform for customized supply-demand analysis, capacity research reports, and detailed regional and product-level supply-demand balance models.